RA
INFI

Royce & Associates’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Royce & Associates’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-135,400
Closed -$1.82M – 1402
2014
Q3 		$1.82M Buy
135,400
+12,000
+10% +$143K 0.01% 1028
2014
Q2 		$1.57M Buy
+123,400
New +$1.29M ﹤0.01% 1082

Other funds holding INFI

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Royce & Associates's INFI Position: Q4 2014 in Review

Royce & Associates sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2014, closing a stake of 135,400 shares — an estimated $1.82M sold.

Royce & Associates first reported a position in INFI in Q2 2014 and held it in 2 quarters. The position peaked at $1.82M in Q3 2014. 143 funds tracked by Wall St. Rank hold INFI as of Q4 2014.

  • Royce & Associates reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • Royce & Associates sold 135,400 Infinity Pharmaceuticals, Inc. shares in Q4 2014, an estimated $1.82M.
  • Royce & Associates first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2014 and held it in 2 quarters.
  • Royce & Associates's Infinity Pharmaceuticals, Inc. position peaked at $1.82M in Q3 2014.
  • 143 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2014.

Based on Royce & Associates's 13F filing for Q4 2014, filed 9 Feb 2015.